Germany outlines how to track a nasal polyp drug's real-world performance

German health authorities have issued guidance for evaluating mepolizumab's effectiveness in treating chronic rhinosinusitis with nasal polyps in routine clinical practice. The recommendations matter to payers and hospital systems deciding whether the expensive biologic therapy delivers value for their patients and budgets.

Originaltitel: Recommendations for reviewing the effectiveness and documentation of the course of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) in the German healthcare system